What is ChromaTan?
ChromaTan is a specialized innovator in the bioprocessing sector, primarily recognized for its development of continuous column-free chromatography technology. The company's flagship offering, the Kascade BioRMB, represents a significant departure from traditional purification methods, providing a scalable and highly efficient solution for sensitive biological modalities, including gene therapy products and fusion proteins. By utilizing a disposable, fully closed flowpath, ChromaTan effectively reduces operational overhead while simplifying the complex validation processes typically associated with biomanufacturing. This unique value proposition positions the firm as a critical partner for biomanufacturers seeking to enhance productivity and maintain high product quality standards in an increasingly competitive market.
How much funding has ChromaTan raised?
ChromaTan has raised a total of $142K across 1 funding round:
Debt
$142K
Debt (2021): $142K with participation from PPP
Key Investors in ChromaTan
PPP
Public-Private Partnership
What's next for ChromaTan?
With the infusion of this latest capital, ChromaTan is poised to scale its commercial operations and deepen its penetration into the biomanufacturing market. The company's strategic roadmap likely involves expanding its manufacturing capacity to meet the growing demand for gene therapy purification solutions. Furthermore, the focus will remain on refining the Kascade BioRMB platform to ensure it remains at the forefront of bioprocessing efficiency. By leveraging this financial backing, ChromaTan aims to solidify its market position, fostering long-term partnerships with major biopharmaceutical entities and driving the next generation of purification technology. The company is clearly transitioning from a development-focused entity to a commercial-scale powerhouse, setting the stage for sustained growth and industry-wide adoption of its column-free chromatography systems.
See full ChromaTan company page
